Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease
The Journal of Pharmacology and Experimental Therapeutics · 2023-07 · 386 (1) · 15-25
DOI: 10.1124/jpet.122.001563 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023-07. Verfasst von Anbukkarasi Muniyandi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute (A.M., G.D.H., Y.S., M.R.K., T.W.C.), Department of Pediatrics, Herman B Wells Ce…. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Macular Degeneration, Retinopathy of Prematurity. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NEI NIH HHS.
Abstract (Originalsprache)
Neovascular eye diseases include conditions such as retinopathy of prematurity, proliferative diabetic retinopathy, and neovascular age-related macular degeneration. Together, they are a major cause of vision loss and blindness worldwide. The current therapeutic mainstay for these diseases is intravitreal injections of biologics targeting vascular endothelial growth factor (VEGF) signaling. Lack of universal response to these anti-VEGF agents coupled with the challenging delivery method underscore a need for new therapeutic targets and agents. In particular, proteins that mediate both inflammatory and proangiogenic signaling are appealing targets for new therapeutic development. Here, we review agents currently in clinical trials and highlight some promising targets in preclinical and early clinical development, focusing on the redox-regulatory transcriptional activator APE1/Ref-1, the bioactive lipid modulator soluble epoxide hydrolase, the transcription factor RUNX1, and others. Small molecules targeting each of these proteins show promise for blocking neovascularization and inflammation. The affected signaling pathways illustrate the potential of new antiangiogenic strategies for posterior ocular disease. SIGNIFICANCE STATEMENT: Discovery and therapeutic targeting of new angiogenesis mediators is necessary to improve treatment of blinding eye diseases like retinopathy of prematurity, diabetic retinopathy, and neovascular age-related macular degeneration. Novel targets undergoing evaluation and drug discovery work include proteins important for both angiogenesis and inflammation signaling, including APE1/Ref-1, soluble epoxide hydrolase, RUNX1, and others.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute (A.M., G.D.H., Y.S., M.R.K., T.W.C.), Department of Pediatrics, Herman B Wells Center for Pediatric Research (M.M., M.R.K.), Stark Neurosciences Resear…
ORCID-Profile: Anbukkarasi Muniyandi, Mark R Kelley, Timothy W Corson
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NEI NIH HHS
Zitieren
APA
Muniyandi, A., Hartman, G. D., Song, Y., Mijit, M., Kelley, M. R., & Corson, T. W. (2023). Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease. The Journal of Pharmacology and Experimental Therapeutics, 386(1), 15-25. https://doi.org/10.1124/jpet.122.001563
Vancouver
Muniyandi A, Hartman GD, Song Y, Mijit M, Kelley MR, Corson TW. Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease. The Journal of Pharmacology and Experimental Therapeutics. 2023;386(1):15-25. doi:10.1124/jpet.122.001563
BibTeX
@article{Muniyandi2023,
author = {Muniyandi, Anbukkarasi and Hartman, Gabriella D and Song, Yang and Mijit, Mahmut and Kelley, Mark R and Corson, Timothy W},
title = {Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2023},
volume = {386},
number = {1},
pages = {15--25},
doi = {10.1124/jpet.122.001563}
}
EUVIMED